The two organizations will produce educational materials about the medicine and its importance for people living with type 1 and 2 diabetes.
The American Diabetes Association (ADA) announced a multiyear strategic partnership with Xeris Pharmaceuticals. The two organizations will work together on a campaign to raise awareness about the importance of glucagon.
According to the ADA, nearly half of all people with type 1 diabetes suffer from at least one severe hypoglycemia event each year. For people with type 2 diabetes, that number is about 21%. Glucagon is an effective treatment to prevent this, although the ADA notes that it is still under prescribed. As part of its partnership with Xeris, the ADA will produce educational materials aimed about both health care professionals and patients.
In a press release, the ADA’s CEO Charles Henderson said, “Severe hypoglycemia is life-threatening, and people with diabetes on blood glucose-lowering medication are at risk for hypoglycemia. Thus, we must act with urgency to educate people about the importance of having a treatment plan in place that includes having glucagon on hand. Through this important partnership, we can save lives by ensuring individuals with diabetes who are treated with insulin have access to glucagon, preferably a ready-to-use formulation, so they can make a plan and be ready."
In the same press release, Xeris’ CEO John Shannon added, “Severe hypoglycemia is associated with up to a three-time increased risk of death in people with diabetes.4,5,6 Xeris is proud to collaborate with the ADA to urge adoption of their strengthened clinical practice recommendations around the treatment of severe hypoglycemia. The stakes are too high for so many patients at risk to be without a safety net. Our mutual commitment is to fight for all patients living with diabetes and ensure that they can face severe low blood glucose emergencies with confidence by always having a ready-to-use glucagon on hand."
The importance of Glucagon is noted in the ADA’s updated Standards of Care for 2025, which the organization announced in December, 2024.2 At the time, the ADA’s senior vice president of health care improvement Nuha El Sayed, MD, MMSc, noted, “"The latest ADA guidelines combine comprehensive, evidence-based recommendations for diabetes care with actionable guidance to enable health care professionals provide the best care possible for those living with diabetes.”
The ADA regularly partners with organizations for various educational campaigns related to the treatment of diabetes. In November 2024, the organization announced a partnership with Estes Express Lines. As a result, the freight carrier decorated its trailers with decals promoting the Drive Out Diabetes campaign.3
In a press release issued at the time, Estes president and COO Webb Estes said, “By leveraging our presence on roadways all over the country, we're able to raise awareness and reach more people about important causes, like diabetes. We look forward to seeing the impact of this new program and letting everyone know about the causes and nonprofits that Team Estes supports and believes in."
Chair of the ADA’s board of directors Rhodes Ritenour added, “American Diabetes Month is the perfect time to roll out this unique way of raising awareness about diabetes. We're grateful to Estes Express Lines for joining us in the fight to improve the lives of people affected by diabetes—and ultimately to find a cure."
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Novel GLP-1 Receptor Agonist Demonstrates Promising Results Treating Patients with Obesity
January 21st 2025Data from a Phase Ia single ascending dose study found that ASC30 demonstrated dose-proportional pharmacokinetics, a half-life of up to 60 hours, and superior pharmacokinetic properties compared to other oral GLP-1 receptor agonists.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.